The final thesis of Professor Lim Soo's team of the Department of Endocrine Metabolism at Bundang Seoul National University ...

SAN DIEGO -- Benefits with empagliflozin (Jardiance) for cardiovascular and renal health linger for about a year after discontinuation, as off-drug follow-up from the EMPA-KIDNEY trial showed. During ...

Use of SGLT2 inhibitors rather than GLP-1 receptor agonists is associated with lower risk of progression to kidney replacement therapy among patients with type 2 diabetes and CKD. The risk of ...

MADRID — Nearly half of people with type 2 diabetes (T2D) currently recommended to receive sodium-glucose cotransporter 2 (SGLT2) inhibitors for kidney protection would not actually benefit from them, ...

In patients with type 2 diabetes (T2D) and metabolic dysfunction–associated steatotic liver disease (MASLD), the risk for major liver outcomes appears similar with dipeptidyl peptidase 4 (DPP-4) and ...

Please provide your email address to receive an email when new articles are posted on . Overall, 44% of the calorie restriction and dapaglifozin treatment group achieved diabetes remission compared ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Patients with ...

Compared with DPP-4 inhibitors, SGLT-2 inhibitors were linked to a lower risk for incidental Parkinson disease among older adults with type 2 diabetes. Use of sodium-glucose cotransporter-2 (SGLT-2) ...

Greatest increase in SGLT2 inhibitor use seen in subgroups with cardiovascular disease; greatest increase in GLP-1 RA for those with obesity. HealthDay News — From 2010 to 2023, there was an increase ...

SGLT2 inhibitor use was associated with lower risks for dementia and cardiovascular events among patients with diabetes and atrial fibrillation. Sodium-glucose cotransporter-2 (SGLT2) inhibitor use is ...